CRISPR Therapeutics AG CRSP shares are trading lower Monday after Morgan Stanley maintained the company with an Underweight rating and lowered the price target.
What To Know:
On Monday, Morgan Stanley analyst Terence Flynn maintained CRISPR Therapeutics with an Underweight and lowered the price target from $43 to $42.
Last Tuesday, RBC Capital analyst Luca Issi maintains CRISPR Therapeutics with a Sector Perform and lowered the price target from $55 to $50.
Also, Needham analyst Gil Blum maintained CRISPR Therapeutics with a Buy and lowered the price target from $88 to $85.
CRISPR Therapeutics reported third-quarter losses of $1.41 per share last Monday, beating the analyst consensus estimate of loss of $1.96 per share.
CRISPR Therapeutics shares have attracted attention from retail investors as well as short-sellers. The stock is one of the top trending tickers on Yahoo Finance, and 17.72% of available CRSP shares are being sold short, according to data from Benzinga Pro.
Related News: What's Going On With Tivic Health Systems Inc Stock?
CRSP Price Action: According to Benzinga Pro, CRISPR Therapeutics shares are down 7% at $49.39 at the time of publication.
Image: Arek Socha from Pixabay
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
